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Abstract
The objective of this study was to evaluate the chemopreventive effect of a novel flavonoid, ampelopsin (AMP) on the
growth and metastasis of prostate cancer cells. AMP showed the more potent activity in inhibiting the proliferation of
androgen-sensitive LNCaP and, to less extent, androgen-independent PC-3 human prostate cancer cell lines in vitro,
primarily by induction of apoptosis associated with down-regulation of bcl-2. On the other hand, AMP showed much less
activity in inhibiting the proliferation of normal prostate epithelial cells than that of prostate cancer cell lines. AMP also
inhibited the migration and invasion of PC-3 cells in vitro associated with down-regulation of CXCR4 expression. In the
animal study using an orthotopic prostate tumor model, AMP (150 and 300 mg/kg body weight) inhibited the growth of
PC-3 tumors and lymph node and lung metastases in a dose-dependent manner. Compared to the control mice, mice
treated with AMP at 300 mg/kg BW had reduced final tumor weight by 49.2% (P,0.05), lymph node metastases by 54.5%
(P=0.3) and lung metastases by 93% (P,0.05), but had no apparent alteration on food intake or body weight. The in vivo
anti-growth and anti-metastasis activities of AMP were associated with induction of apoptosis and inhibition of proliferation
of prostate cancer cells, reduction of prostate tumor angiogenesis, and reduction of CXCR4 expression. Our results provide
supporting evidence to warrant further investigation to develop AMP as a novel efficacious and safe candidate agent
against progression and metastasis of prostate cancer.
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Introduction
Prostate cancer is the most common invasive malignancy and
the second-leading cause of cancer death in men in the U.S. It is
estimated that 241,740 new cases of prostate cancer would be
diagnosed and about 28,170 men would die of prostate cancer in
the United States in 2012 [1]. Current therapeutic modalities for
prostate cancer usually have variable effectiveness, develop
metastasis and drug-resistance, and have high toxicity to normal
tissues. Therefore, the searching for effective regimens with
moderate adverse effects for the chemopreventive intervention of
prostate cancer remains the top priority in prostate cancer
research.
Bioactive components in botanicals and herbal medicines may
provide effective and safe candidates for chemoprevention and/or
therapy of cancer. Classical Chinese medical texts contain
extensive empirical records of botanical therapies used to treat
patients with cancer and cancer-related systems. However, most of
these candidate botanical formulas are recommended based on
clinical observations only. Moreover, these clinical observations
were almost always from uncontrolled, observational studies or
anecdotal case reports. Until very recently, there has been limited
effort to develop preclinical, mechanistic, scientific evaluation of
botanical herbal products as a prerequisite for human clinical
studies.
The Chinese herb Ampelopsis grossedentata is widely distributed in
South China and is used to treat cold and tinea corporis. It
contains a rich resource of phytochemicals with ampelopsin (AMP,
(2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydro-
chromen-4-one) the major flavonoid. AMP is also called
dihydromyricetin and has a similar structure to myricetin (3,5,7-
trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone), a naturally
occurring flavonoid found in grapes, berries, fruits, vegetables,
herbs and other plants with certain anti-cancer activities. As the
major bioactive constituent of Ampelopsis grossedentata, AMP was
shown to be mainly responsible for the reported biological
activities, including hypoglycemic [2], anti-oxidative [3,4] and
hepatoprotective [4,5] activities. AMP also enhanced the chemo-
kinesis and chemotaxis effects of neutrophilic granulocytes and
monocytes [6].
AMP was shown to possess certain anti-cancer activities. AMP
inhibited the growth [7] and invasion of melanoma cells in vitro
[8,9], and inhibited metastasis of melanoma tumor in vivo [8,9].
AMP inhibited the growth of lung tumors in vivo by inhibiting
proliferation [10]. AMP had anti-angiogenesis activity by inhib-
iting the secretion of vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF) from human hepato-
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human hepatocellular carcinoma in mice [11]. AMP also reversed
multidrug resistance in leukemia cells in vitro in part via
decreasing the expression of p-glycoprotein [12]. On the other
hand, the effect of AMP on the growth and progression of prostate
cancer has not been studied.
The objectives of this study were to systematically evaluate
AMP as a potential chemopreventive and therapeutic candidate
against prostate cancer progression by using both in vitro and in
vivo systems, and to elucidate the underlying cellular and
molecular mechanisms of AMP actions. Our results provided
experimental evidence to support the future development of AMP
as an effective and safe candidate agent for the prevention and/or
therapy of prostate cancer.
Results
Effects of AMP, total flavonoid extract (TFE) and myricetin
on the proliferation of prostate cancer cell lines and
normal prostate epithelial cells (PrEC) in vitro
We first compared the activity among AMP, TFE and myricetin
in inhibiting the proliferation of prostate cancer cell lines and
PrEC. The AMP purity analysis by high performance liquid
chromatography (HPLC) showed that AMP purity was about
95%, and the representative HPLC chromatogram was shown in
Fig. S1. TFE concentrations were calculated based on its AMP
level, thus the difference of activity between TFE and AMP is
attributed to other phytochemicals in TFE. As shown in Fig. 1 (A,
B, C), AMP and TFE showed the similar activities in inhibiting the
proliferation of prostate cancer cells or normal prostate cells,
suggesting that AMP is the major bioactive flavonoid in TFE.
AMP or TFE inhibited the proliferation of LNCaP cell line at the
IC50’s about 25 mM (Fig. 1A), and that of PC-3 cell line at the
IC50’s about 60 mM (Fig. 1B). On the other hand, AMP or TFE
showed much less activity in inhibiting the proliferation of normal
prostate epithelial cells than that of prostate cancer cell lines
(Fig. 1C), suggesting that AMP or TFE may have moderate/
minimal side effect.
On contrast, myricetin showed more potent activity in
inhibiting the proliferation of PrEC than that of LNCaP or PC-
3. Although myricetin inhibited the growth of prostate cancer cell
lines at the IC50s .60 mM (Fig. 1A, 1B), it inhibited the growth
PrEC cells at the IC50 about 35 mM (Fig 1C). Because of the
potent anti-cancer activity and minimal side effect of AMP, it was
used for further evaluation.
Effects of AMP on cell cycle progression of prostate
cancer cell lines in vitro
AMP at 25 and 50 mM significantly increased the fraction of
LNCaP cells at S phase from 20% to 28% (P,0.05) and 74%
(P,0.001), respectively (Fig. 2B). On the other hand, AMP at 25
and 50 mM increased the fraction of PC-3 cells at S phase from
22% to 28% (P.0.05) and 34% (P,0.05), respectively (Fig. 2E),
and at G2/M phases from 17% to 23% (P,0.05) and 24%
(P,0.05), respectively (Fig. 2F).
Several cell cycle related biomarkers, such as cell division cycle 2
(CDC2), CDC25c, cyclin B1 and cyclin-dependent kinase 2
(CDK2), were determined by Western blot analysis. AMP
significantly downregulated CDK2 protein level in LNCaP cells
(Fig. 3B, 3C) and CDC2 protein level in PC-3 cells (Fig. 3E, 3F),
but not other cell cycle related biomarkers.
Effects of AMP on apoptosis induction of prostate cancer
cell lines in vitro
AMP also significantly increased prostate cancer cell DNA
fragmentation, a hallmark for apoptosis. AMP at 25 and 50 mM
significantly induced DNA fragmentation of LNCaP cells by 15-
fold (P,0.001) and 70-fold (P,0.001) respectively (Fig. 3A), and
PC-3 cells by 86% (P,0.05) and 270% (P,0.001) respectively
(Fig. 3D), compared with the corresponding controls. LNCaP cells
were further treated with AMP at 25 and 50 mM and apoptosis
related molecular biomarkers were determined by Western blot
analysis. AMP induced apoptosis of LNCaP and PC-3 cells
associated with downregulation of Bcl-2 (Fig. 3B, 3C, 3E, 3F).
The apoptosis induction effect of AMP on PC-3 cell line was
further confirmed using the Annexin V-PI flow cytometry assay.
Figure 1. Effects of AMP, TFE and myricetin on the proliferation of human prostate cancer cells and normal prostate epithelial cells
(PrEC) in vitro after 72 hr of treatments. A: The dose-dependent effects of AMP, TFE and myricetin on the proliferation of androgen-sensitive
LNCaP cell line; B: The dose-dependent effects of AMP, TFE and myricetin on the proliferation of androgen-independent PC-3 cell line; C: The dose-
dependent effects of AMP, TFE and myricetin on the proliferation of PrEC. Values are means6SEM of at least three independent experiments, each in
triplicates.
doi:10.1371/journal.pone.0038802.g001
Flavonoid Ampelopsin and Prostate Cancer
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38802AMP showed dose- and time- dependent effects on inducing PC-3
cell apoptosis (Fig. S2).
Effects of AMP on migration and invasion of PC-3 cells
and downregulation of CXCR4 protein level in vitro
PC-3 cell line was used to evaluate the effect of AMP on
prostate cancer cell migration and invasion. AMP at 25 and
50 mM significantly inhibited PC-3 cell migration by 26%
(P,0.05) and 63% (P,0.01), respectively (Fig. 4A), and invasion
by 27% (P,0.05) and 45% (P,0.01), respectively (Fig. 4B). The
inhibitory effect of AMP on PC-3 cell migration and invasion was
associated with downregulation of CXCR4 protein level (Fig. 4C,
4D), an important biomarker for cancer cell invasion and
metastasis. Under the experimental condition (16-hr treatment),
AMP did not cause PC-3 cell cytotoxicity, as measured by the
trypan blue assay (Fig. S3). It suggests that the observed anti-
migration and anti-invasion activities of AMP are not secondarily
due to its cytotixicity.
Effects of AMP on the growth and metastasis of
androgen-independent PC-3 prostate tumors and
modulation of tumor cell proliferation, apoptosis and
CXCR4 expression and tumor angiogenesis in mice
An orthotopic PC-3 tumor animal model was used to evaluate
the effect of AMP on preventing the growth and metastasis of
prostate tumor. AMP inhibited both tumor growth and metastasis
in vivo in a dose-dependent manner. AMP at 150 and 300 mg/kg
BW reduced the final tumor weight by 28% (P.0.05) and 52%
(P,0.05) respectively (Fig. 5A), inhibited lymph nodes metastases
by 27% (P.0.05) and 43% (P.0.05) respectively (Fig. 5B), and
inhibited lung metastases by 57% (P.0.05) and 86% (P,0.05)
respectively (Fig. 5C). The representative images of lung metas-
tases are shown in Fig. S4. On the other hand, AMP treatments
did not significantly alter total food intake (Fig. 5D) or final body
weight (Fig. 5E).
Analyses of cellular markers showed that AMP treatment
significantly induced prostate cancer cell apoptosis by 200%
(Fig. 6A, P,0.001), reduced prostate cancer cell proliferation by
60% (Fig. 6B, P,0.001) and inhibited prostate tumor angiogenesis
by 58% (Fig. 6C, P,0.05). These results confirmed that AMP
inhibited the growth of prostate tumors by inducing apoptosis,
reducing proliferation, and inhibiting prostate tumor angiogenesis
in vivo. The representative images of cellular biomarkers are
shown in Fig. S5. The AMP treatment also reduced CXCR4
protein expression by 30% in prostate tumors (Fig. 6D, P,0.05).
Discussion
In the present study, we found that AMP significantly inhibited
the proliferation of prostate cancer cell lines via apoptosis
induction associated with downregulation of Bcl2 expression,
Figure 2. Effects of AMP on cell cycle progression of prostate cancer cell lines in vitro. A, B, and C: The dose-dependent effect of AMP on
the distribution of LNCaP cells at G1 (A), S (B) and G2/M (C) phases; D, E, and F: The dose-dependent effect of AMP on the distribution of PC-3 cells at
G1 (D), S (E) and G2/M (F) phases. Values are mean6SEM of three independent experiments, each in duplicates. Within the panel, the value with a
letter is significantly different from that of the control, a, p,0.05; b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0038802.g002
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associated with downregulation of CXCR4 expression in vitro.
The animal study further confirmed that AMP significantly
reduced the final tumor weight associated with inducing prostate
cancer cell apoptosis, inhibiting prostate cancer cell proliferation
and reducing prostate tumor angiogenesis, and significantly
inhibited lung metastases. On the other hand, AMP at effective
doses did not show significant adverse effect on food intake or
body weight. This is the first study, to the best of our knowledge,
that demonstrated the inhibitory effect of AMP on the growth and
metastasis of prostate cancer in vitro and in a clinically relevant
orthotopic tumor model.
Cellular mechanism studies showed that AMP inhibited the
proliferation of prostate cancer cells. Interestingly, AMP arrested
LNCaP cells at S phase (Fig. 2B) in part via down regulation of
CDK2 (Fig. 3B, 3C), a biomarker essential for the G1/S
transition, whereas it arrested PC-3 cells at S and G2/M phases
(Fig. 2E, 2F) associated with downregulation of CDC2 (Fig. 3E,
3F). CDC2, also known as CDK1 (cyclin dependent kinase 1),
plays an important role during the cell cycle progress. CDC2
usually combines with cyclin B and regulates the S and G2/M
phase progression. CDC2 has been considered as an essential
molecular target for design of therapeutic anti-cancer drugs [13].
Down-regulation of CDC2 may provide an important molecular
mechanism that AMP arrests cell cycle progression of PC-3 cells at
S and G2/M phases. Analysis of in vivo tumor samples also
confirmed that AMP inhibited PC-3 tumor growth associated with
inhibition of tumor cell proliferation (Fig. 6B).
Induction of prostate cancer cell apoptosis is also an important
mechanism by which AMP inhibit the growth of prostate cancer.
AMP induced apoptosis of prostate cancer cells in vitro (Fig. 3A,
3D) and in vivo (Fig. 6A). Further investigation showed that
induction of apoptosis was associated with down regulation of bcl-
2 protein levels (Fig. 3C, 3F). Bcl-2 is an important regulator of
apoptosis. Expression of bcl-2 is more frequent in high-grade
tumors and metastases than in lower-grade and nonmetastatic
tumors [14,15]. Apoptosis resistance is associated with higher
levels of bcl-2 [15,16], and downregulation of bcl-2 sensitizes
prostate cancer cells to undergo apoptosis [17]. Therefore,
downregulation of bcl-2 could represent an important molecular
mechanism by which AMP induces prostate cancer apoptosis.
Angiogenesis is a critical step in tumor growth [18]. The growth
of all solid tumors depends on angiogenesis and suppression of
tumor blood vessel offers a new option for the prevention and
Figure 3. Effects of AMP on apoptosis of prostate cancer cells and on protein levels of biomarkers. A and D: The dose-dependent effect
of AMP on the proportion of DNA fragmentation (sub-G0), a marker of apoptosis, in LNCaP (A) and PC-3 (D) cell lines; B and E: The representative
Western blot images showing the effects of AMP on protein levels of cell cycle progression and apoptosis related biomarkers in LNCaP (B) and PC-3
(E) cell lines; C and F: Quantitation of significantly altered protein levels in LNCaP (C) and PC-3 (F) cell lines by densitometry after normalization to b-
actin. The images for quantitation were from at least two independent experiments. Values are mean6SEM of three independent experiments, each
in duplicates. Within the panel, the value with a letter is significantly different from that of the control, a, p,0.05; b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0038802.g003
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anti-angiogenesis activity by inhibiting the secretion of pro-
angiogenic factor VEGF and bFGF from human hepatocellular
carcinoma cells in vitro [11]. In this study, we demonstrated that
AMP inhibited the growth of PC-3 prostate tumor associated with
inhibition of tumor angiogenesis (Fig. 6C). Although we did not
measure the VEGF and bFGF levels in vivo, our results provided
suggestive experimental evidence to support that one of the
mechanisms by which AMP inhibits tumor growth is via inhibiting
angiogenesis. Further investigation is needed to determine the
underlying molecular mechanisms that AMP inhibits tumor
angiogenesis.
Previous studies have shown that AMP inhibited the in vitro
invasion and in vivo metastasis ability of B16 melanoma [8].
However, it has not been studied if AMP had anti-metastasis
activity in prostate cancer. Our results demonstrated that AMP
had potent activities in inhibiting migration and invasion of
prostate cancer cells in vitro and prostate cancer metastasis in the
orthotopic prostate tumor animal model associated with down-
regulation of CXCR4 expression. CXCR4 is involved in several
diseases such as angiogenesis, metabolic and neurological disor-
ders, rheumatoid arthritis and in different forms of metastatic
cancer. CXCR4 is a critical factor in the invasiveness and
proliferation of breast cancer cells [20,21,22] and plays a pivotal
role for the growth of malignant neuronal and glial tumors [23].
CXCR4 inhibitors are suggested for the treatment of different
forms of metastatic cancer [24,25,26]. AMP is shown to be a small
molecule CXCR4 antagonist [27,28]. Although we did not study if
CXCR4 was a direct molecular target for AMP, our studies
suggest that one of the molecular mechanisms by which AMP
inhibits prostate cancer metastasis may be via downregulation of
CXCR4 expression and function. Further investigation in
applying AMP and/or its derivatives as novel anti-metastasis
agents for delaying and/or preventing cancer metastasis could
have significant impacts on prevention and therapy of cancer.
In conclusion, the results from this study provided critically
important experimental evidence to suggest that AMP may be a
novel efficacious and safe candidate agent to inhibit the growth
and metastasis of prostate cancer.
Materials and Methods
Ethics statement
All procedures with animals were reviewed and approved by the
Institutional Animal Care and Use Committee at Beth Israel
Deaconess Medical Center with the Guide for the Care and Use of
Laboratory Animals.
TFE, AMP and myricetin
A proprietary extraction procedure was applied to extract TFE
from Ampelopsis grossedentata with AMP content at approximately
80%. AMP was purified from TFE by preparative HPLC; and the
purity was verified by analytical reverse phase HPLC. Myricetin
was purchased from LKT Laboratories (St. Paul, MN). HPLC
Figure 4. Effects of AMP on migration and invasion of PC-3 cells and CXCR4 protein levels in vitro. A: The dose-dependent effect of AMP
on migration of PC-3 cells; B: The dose-dependent effect of AMP on invasion of PC-3 cells; C: The dose-dependent effect of AMP on CXCR4 protein
levels in PC-3 cells; D: Quantitation of CXCR4 protein levels in PC-3 cells by densitometry after normalization to b-actin. Values are mean6SEM of
three independent experiments, each in duplicate. Within the panel, the value with a letter is significantly different from that of the control, a,
p,0.05; b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0038802.g004
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materials were dissolved in dimethyl sulfoxide (DMSO) for cell
culture studies.
Culture of prostate cancer cells, normal prostate
epithelial cells and endothelial cells
Two human prostate cancer cell lines, androgen-sensitive
LNCaP and androgen-independent PC-3 (American Type Culture
Collection, Bethesda, MD) were used for the in vitro experiments.
Human prostate cancer cell lines were maintained as monolayer
cultures in DMEM medium supplemented with 10% fetal bovine
serum, 2 mmol L-glutamine/mL, 100 U penicillin/mL and
100 mg streptomycin/mL in a 95% air, 5% CO2, and water-
saturated atmosphere. PrEC cells were purchased from Lonza
(Walkersville, MD) and cultured in PrEGM plus EGM-2
singlequotes (Lonza, Walkersville, MD) in a humidified atmo-
sphere of 95% air and 5% CO2.
Cell growth
The effect of AMP, TFE and myricetin on the cytotoxicity of
prostate cancer cells or PrEC was determined using the Cell Titer
96 Aqueous Cell Proliferation Assay (Promega, Madison, WI) as
we previously described [29]. The assay determines the number of
viable cells in proliferation, cytotoxicity and chemosensitivity. All
assays were independently repeated at least thrice, each in
triplicate, and results were confirmed by direct cell counting using
a hemocytometer.
Analysis of prostate cancer cell cycle progression and
DNA fragmentation
The effect of AMP treatment on cell cycle distribution of
prostate cancer cell lines was determined by flow cytometry
following the described procedures [30]. Cells treated with
different concentration of AMP were harvested, stained with
propidium iodide (at a final concentration of 50 mg/ml) and
RNase (at a final concentration of 50 mg/ml), and incubated at
37uC for 30 min. Stained cells were then analyzed by FACScan
(Becton Dickinson, Immunocytometry Systems, Mountview, CA)
for cell cycle distribution and fragmented DNA. The experiments
were independently repeated at least thrice, each in duplicate.
Annexin V and PI staining for apoptosis detection
The effect of AMP on the apoptosis of PC-3 cells was further
determined by Annexin V-PI apoptosis detection kit (Chemicon
International Inc, Billerica, MA) following the instruction of kit.
Briefly, treated PC-3 cells were resuspended in Annexin V solution
and incubated at room temperature for 15 min, PI was then added
for another 5-min incubation in the dark. Apoptotic cells were
analyzed by flow cytometry (Becton Dickinson, Immunocytometry
Systems, Mountview, CA). The experiments were independently
performed at least twice, each in duplicates.
Cancer cell migration and invasion assays
A suspension of PC3 cells (6000 cells for migration and 30000
cells for invasion) in 250 mL of serum-free DMEM with AMP or
Figure 5. Effects of AMP treatment at 150 and 300 mg/kg BW on final PC-3 tumor weight (A), lymph node metastases (B), lung
metastases (C), total food intake (D) and final body weight (E). Values are group mean6SEM (n=8/group). Within the panel, the value with a
letter is significantly different from that of the control, a, p,0.05.
doi:10.1371/journal.pone.0038802.g005
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migration assay or a matrigel-coated insert for invasion assay
(Biocoat, 24-well plate, 8 mm, Becton Dickinson). Each culture
insert was set into a well containing 750 mL of DMEM with 5%
FBS. After incubation for 16 hrs at 37uC, cells on the top of inserts
were removed carefully using a cotton tip, and the cells on the
underside of the insert membrane were stained with Diff-Quick
Stain solutions (Dade Behring Inc., Newark, DE) and the images
were captured. Cells were counted under a microscope. All assays
were independently performed at least thrice, each in triplicate.
To confirm that the anti-migration and anti-invasion activities
of AMP were not secondarily due to its cytotoxicity to PC-3 cells,
PC-3 cells were treated with AMP (0, 25, and 50 mM) for 16 hr,
and the cell numbers were measured by trypan blue exclusion
assay. The experiment was independently performed at least
thrice, each in duplicate.
Western blot analysis
For the in vitro study, cells were treated with different
concentrations of AMP, cell lysates were prepared, and protein
levels were determined by Western blot analysis following the
procedures we described previously [31]. The primary antibodies
used in Western blot against human antigens were as follows:
cyclin B1 (1:200), cdc2 (1:500) and bax (1:500) (Oncogene
Research Products, Boston, MA), bcl-2 (1:100), p21 (1:200) and
p53 (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA), CDK2
(1:1,000) (Selleck Chemicals, Houston, TX), CXCR4 (1:200)
(R&D systems, Inc, USA), and b-actin (1:10,000) (Merck Co.,
Darmstadt, Germany). For the in vivo study, tumor samples in
both the control and AMP-treated groups were collected for
Western blot analysis of CXCR4 protein level.
Animal study
The chemopreventive intervention activity of AMP on the
growth and metastasis of PC-3 tumors was determined in an
orthotopic PC-3 tumor animal model. Male severe combined
immune-deficient mice (6–8-week old) were purchased from
Taconic (Germantown, NY), and housed at the animal facility of
Beth Israel Deaconess Medical Center in a pathogen-free
environment equipped with laminar flow hoods and standard
vinyl cages with air filters. After one week of acclimatization and
adaptation to the AIN-93 diet, mice were randomly assigned into
one of the following three experimental groups (in each group,
n=8) and pretreated via gavage daily for 2 weeks: (i) Control: the
vehicle (100 mL corn oil); (ii) AMP at 150 mg/kg body weight
(BW); and (iii) AMP at 300 mg/kg BW. Each mouse was then
implanted orthotopically with PC-3 cells (2610
6 cells/50 mL) and
continued on the corresponding treatments throughout the
experiment. Food intake and body weight were measured weekly.
At the end of the experiment (8 weeks after PC-3 cell
implantation), the mice were sacrificed; primary tumors were
excised and weighed. A tumor slice from each primary tumor
tissue was carefully dissected and fixed in 10% buffer-neutralized
formalin, paraffin-embedded, and sectioned at 4 mm thickness for
immunohistochemistry. All procedures with animals were re-
viewed and approved by the Institutional Animal Care and Use
Committee at Beth Israel Deaconess Medical Center with the
Guide for the Care and Use of Laboratory Animals [32]. The
animal study was repeated.
Figure 6. Effects of AMP treatment on PC-3 tumor cell apoptosis index measured by TUNEL assay (A), tumor cell proliferation
measured by immunohistochemical staining of ki-67 (B), tumor microvessel density measured by Factor VIII staining (C) and tumor
cell expression of CXCR4 measured by Western blot analysis (D). Values are group mean6SEM (n=8/group). Within the panel, the value
with a letter is significantly different from that of the control, a, p,0.05; c, p,0.001.
doi:10.1371/journal.pone.0038802.g006
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Apoptotic cells were determined by a terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate-biotin nick end
labeling (TUNEL) assay (Chemicon International Inc, Billerica,
MA) following our described protocols [30,33,34]. Six represen-
tative areas of each section without necrosis were selected and both
apoptotic cells and total nuclei cells were counted under a light
microscope at 4006 magnification. The apoptotic index was
expressed as the percentage of positive apoptotic tumor cells to
total tumor cells, and the effect of treatment on apoptosis was
expressed as the percentage to the control.
Immunohistochemical determination of tumor cell
proliferation
The proliferation index was evaluated by calculating the
proportion of cells with Ki-67 staining, following the procedures
in the laboratory [31]. Both Ki-67-positive proliferating cells and
total tumor cells were counted in six non-necrotic areas of each
section using light microscope at 4006 magnification. The
proliferation index was calculated as the percentage of Ki-67-
positive tumor cells to total tumor cells, and the effect of treatment
on proliferation was expressed as the percentage to the control.
Immunohistochemical detection of microvessel density
(MVD)
MVD was used as a marker for tumor angiogenesis and
quantified by immunohistochemical staining of Factor VIII
following our previously described method [30,33,34]. MVD
was calculated by counting microvessels on 2006fields under light
microscopy at six representative sites without necrosis of each
section, and the effect of treatment on angiogenesis was expressed
as the percentage to the control.
Statistical analysis
Results were expressed as group means6SEM and analyzed for
statistical significance by analysis of variance [35] followed by
Fisher’s protected least-significant difference based on two-side
comparisons among experimental groups using Statview 5.0
program (SAS Institute, Inc., Cary, NC). A P,0.05 was
considered statistically significant.
Supporting Information
Figure S1 The representative chromatogram showing
the purity of AMP by analytical reverse phase HPLC.
HPLC experimental conditions were: Instrument: Waters 2695
with auto-sampler and the photo diode array (PDA) detector;
HPLC column: Phenomenox C-18 (5 mm in inner diameter,
106250 mm); Mobile phases: A (H2O with 0.1% acetic acid) and
B (acetonitrile); Gradient condition: 0–30 min, 5% B to 35% B;
30–35 min, 35% B to 95% B; 35–40 min, 95% B to 5% B; 40–
45 min, 5% B; Flow rate: 1 ml/min.
(TIF)
Figure S2 Representative FACS histograms showing the
time-dependent effect of AMP treatments (0, 20, and
50 mM) on apoptosis of PC-3 cells, as measured by the
Annexin-PI flow cytometry assay.
(TIF)
Figure S3 The effect of AMP on PC-3 cell cytotoxicity, as
measured by the trypan blue exclusion assay. The cells
were treated with AMP at different concentrations for 16 hr, the
same time used for migration and invasion assays. Values are
mean6SEM of three independent experiments, each in dupli-
cates. The values are statistically insignificant among groups.
(TIF)
Figure S4 The representative H&E images showing the
inhibitory effect of AMP at 150 mg/kg body weight (BW)
(B) and 300 mg/kg BW (C) on lung metastases, as
compared with the control group (A).
(TIF)
Figure S5 The representative images showing the
effects of AMP (300 mg/kg BW) on the expression of
cellular biomarkers of proliferation, as measured by ki-
67 staining (A), apoptosis as measured by TUNEL assay
(B) and angiogenesis, as measured by Factor VIII
staining for microvessel density (C).
(TIF)
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